1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Probi AB (publ)

Probi AB (publ)

PBBIF
Probi AB (publ)US flagOther OTC
24.00
USD
- -
- -
286.93MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
9.73
10.39
10.72
14.03
22.36
46.71
53.73
53.02
54.96
62.94
57.76
54.26
55.09
55.33
Basic EPS, GAAP
1.45
1.4
1.56
2.25
5.08
10.73
6.06
6.69
7.54
8.14
7.3
3.57
1.48
0.96
Free Cash Flow per Basic Share
0.74
1.83
1.12
2.44
4.41
7.53
10.48
9.99
12.15
8.78
9.8
8.03
2.75
6.69
Dividend per Share
0.94
0.71
0.71
0.71
0.8
0.96
1
- -
- -
1
1.1
1.3
1.3
1.3
Book Value per Share
4.57
5.3
6.86
8.41
12.68
28.45
28.78
35.47
43.16
50.29
56.49
58.75
58.93
- -
Tangible Book Value per Share
10.01
10.78
10.64
12
14.87
2.52
10.27
20.18
31.08
38.73
50.48
59.17
60.4
62.07
Basic Weighted Avg Shares
10
10
10
10
10
9
11
11
11
11
11
11
11
11
Sales/Revenue/Turnover
95
100
104
136
216
443
612
604
626
717
658
618
628
630
Operating Margin (%)
21.55
17.14
17.52
21.11
27.02
27.05
17
16.74
17.81
17.25
16.6
8.18
1.8
0.49
Depreciation Expense
9
6
5
9
6
33
53
54
72
73
73
86
96
101
Net Income, GAAP
14
14
15
22
49
102
69
76
86
93
83
41
17
11
Effective Tax Rate (%)
27.23
26.29
22.81
22.52
22.27
19.6
25.16
22.64
21.58
22.81
22.61
21.84
3.24
12.29
Profit Margin (%)
14.94
13.45
14.53
16.05
22.71
22.97
11.29
12.62
13.72
12.92
12.63
6.57
2.68
1.73
Working Capital
94
102
101
111
139
-20
84
206
292
324
388
454
462
472
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
47
31
63
54
38
61
Total Equity
116
123
131
146
187
892
885
1,028
1,152
1,115
1,266
1,411
1,369
1,368
Return on Invested Capital (%)
12.43
10.59
10.98
15.79
27.03
14.78
7.15
7.09
7.38
8.01
6.75
2.8
0.75
- -
Return on Capital (%)
37.88
28.19
25.6
29.51
48.16
33.56
14.69
15.68
16.4
16.09
12.63
5.82
2.56
5.01
Return on Common Equity (%)
37.87
28.19
25.6
29.51
48.14
51.87
23.11
20.83
19.17
17.41
13.67
6.19
2.51
3.23

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
15
21
20
LT Borrowings
- -
- -
- -
LT Finance Leases
37
68
61
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
1,942
2,330
2,790

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
553
563
562
Cash, Cash Equivalents & STI
340
305
349
Accounts Receivable, Net
71
115
63
Inventories
127
126
129
Total Current Liabilities
69
93
90
Payables & Accruals
- -
- -
- -
ST Debt
15
21
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.24%
6.17%
-2.94%
Free Cash Flow
24.98%
-15.65%
-65.72%
Net Income, GAAP
15.64%
-19.9%
-58.6%
Sales/Revenue/Turnover
23.77%
1.08%
1.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
155
175
145
144
618
2023
172
144
156
156
628
2024
152
179
144
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1.23
1.75
1.09
- -
3.57
2023
1.69
-0.55
0.56
- -
1.48
2024
0.16
0.71
0.31
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
1.3
- -
- -
1.3
2023
- -
1.3
- -
- -
1.3
2024
- -
1.3
- -
- -
- -

Company Description

APIChat
CEO
Anita Johansen
Full Time Employees
157
Sector
Healthcare
Industry
Biotechnology
Address
Ideongatan 1A Lund Sweden 223 70
IPO Date
Oct 17, 2016
Website
probi.com
Similar Companies
EvoNext Holdings S.A. (EVE.SW)
2cureX AB (publ) (2CUREX.ST)
Celltrion, Inc. (068270.KS)
Anebulo Pharmaceuticals, Inc. (ANEB)
SillaJen, Inc. (215600.KQ)
E-therapeutics Plc (ETXPF)
Business
Probi AB (publ) researches, develops, manufactures and sells clinically documented probiotic and biotic solutions for dietary supplements, functional foods and beverages targeting digestive, immune, mental, metabolic, bone, oral and women's health, as well as healthy aging, children's health, iron absorption and pet nutrition; core offerings include proprietary strains such as Lactiplantibacillus plantarum 299v (LP299V), Probi ClinBac portfolio, LiveBac probiotic blends, BLIS K12 and BLIS M18 for oral care, and finished formats encompassing capsules, tablets, powders, chewables, shots, drinks, frozen desserts and recovery beverages. Founded in 1991 at Lund University in Sweden and headquartered in Lund, the company operates in over 40 markets worldwide as a subsidiary of Symrise AG following Symrise's acquisition of a 90.2% majority stake in late 2024, with full integration progressing into 2025. Recent developments encompass an updated exclusive distribution agreement with BLIS Technologies in October 2025 extending rights to BLIS K12 and M18 strains for human and pet health in the US, Canada and select EMEA markets; strengthened partnership with Clasado Biosciences for synbiotic development; expansion into pet nutrition and active nutrition for energy and recovery; and a 44% reduction in carbon emissions from 2019 baseline with facilities powered by 100% renewable energy.